AK131 / Akesobio - LARVOL DELTA

A Study of AK131 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of AK131 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=130 | Not yet recruiting | Sponsor: Akeso

New P1 trial • Oncology • Solid Tumor

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting (PRNewswire) - "The results and observations in AK131's preclinical study support the development of AK131 as an anti-tumor agent in the clinic: AK131 effectively bound to human PD-1 and CD73 with high affinity. The interaction between PD-1 and its ligand PD-L1 was blocked by AK131 in reporter gene assay. In cellular assays, AK131 effectively promoted the secretion of IFN-γ and IL-2 by T cells in co-culture of PBMCs and Raji-PDL1 cells. Moreover, AK131 inhibited CD73 enzymatic activity and induced endocytosis of CD73. AK131 enhanced the expression of CD69, CD83, HLA-DR and IgM which are markers of B cell activation in an adenosine-independent manner. In in-vivo assay, AK131 successfully inhibited tumor growth in C57BL/6-hPD1/hPDL1/hCD73 transgenic mice MC38-hPDL1-hCD73 tumor syngeneic model."

Preclinical • Oncology